Measuring patient experience of Cytosponge using the Newcastle ENDOPREM.
作者信息
Neilson Laura Jane, Fitzgerald Rebecca C, Deane Jennifer, Debiram-Beecham Irene, Sharp Linda, Rees Colin J
机构信息
Department of Gastroenterology, South Tyneside District Hospital, South Shields, UK.
Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
出版信息
Frontline Gastroenterol. 2022 Oct 19;14(4):355-356. doi: 10.1136/flgastro-2022-102288. eCollection 2023.
Abstract
摘要
相似文献
1
Measuring patient experience of Cytosponge using the Newcastle ENDOPREM.使用纽卡斯尔ENDOPREM量表评估患者对细胞海绵的体验。
Frontline Gastroenterol. 2022 Oct 19;14(4):355-356. doi: 10.1136/flgastro-2022-102288. eCollection 2023.
2
Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.Cytosponge-三叶因子 3 与常规护理在初级保健环境中识别 Barrett 食管：一项多中心、实用、随机对照试验。
Lancet. 2020 Aug 1;396(10247):333-344. doi: 10.1016/S0140-6736(20)31099-0.
3
Patient experiences of Cytosponge: a qualitative study.Cytosponge的患者体验：一项定性研究。
Frontline Gastroenterol. 2023 Sep 11;15(1):28-34. doi: 10.1136/flgastro-2023-102484. eCollection 2024 Jan.
4
The changing spectrum of gastroesophageal reflux disease.胃食管反流病不断变化的谱型
Eur J Cancer Prev. 2002 Jun;11(3):215-9. doi: 10.1097/00008469-200206000-00004.
5
Acceptability of the Cytosponge procedure for detecting Barrett's oesophagus: a qualitative study.用于检测巴雷特食管的细胞海绵检查法的可接受性：一项定性研究
BMJ Open. 2017 Mar 1;7(3):e013901. doi: 10.1136/bmjopen-2016-013901.
6
Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.使用 Cytosponge 生物标志物面板对内镜 Barrett 食管监测进行优先级排序：一项横断面研究及后续真实世界前瞻性试点研究。
Lancet Oncol. 2022 Feb;23(2):270-278. doi: 10.1016/S1470-2045(21)00667-7. Epub 2022 Jan 11.
7
Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.使用微创细胞采样装置对胃食管反流病患者进行巴雷特食管筛查的成本效益
Clin Gastroenterol Hepatol. 2017 Sep;15(9):1397-1404.e7. doi: 10.1016/j.cgh.2017.02.017. Epub 2017 Feb 24.
8
Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens.甲基化panel 是内镜活检和非内镜细胞学标本中 Barrett 食管的诊断生物标志物。
Gut. 2018 Nov;67(11):1942-1949. doi: 10.1136/gutjnl-2017-314026. Epub 2017 Oct 30.
9
Oesophageal disease: gastroesophageal reflux disease, Barrett's oesophagus, achalasia and eosinophilic oesophagitis.食管疾病：胃食管反流病、巴雷特食管、贲门失弛缓症和嗜酸性粒细胞性食管炎。
Gastroenterol Hepatol. 2016 Sep;39 Suppl 1:47-52. doi: 10.1016/S0210-5705(16)30174-1.
10
Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.巴雷特食管 3 期临床试验（BEST3）：一项随机对照试验的研究方案，比较 Cytosponge-TFF3 检测与常规护理在初级保健慢性酸反流患者中促进食管前癌诊断的效果。
BMC Cancer. 2018 Aug 3;18(1):784. doi: 10.1186/s12885-018-4664-3.
引用本文的文献
1
Use of a Non-Endoscopic Capsule-Sponge Triage Test for Reflux Symptoms: Results From the NHS England Prospective Real-World Evaluation.使用非内镜胶囊海绵分流试验评估反流症状：英国国家医疗服务体系（NHS）英格兰前瞻性真实世界评估结果
Aliment Pharmacol Ther. 2025 Mar;61(5):876-885. doi: 10.1111/apt.18472. Epub 2025 Jan 10.
2
Patient experiences of Cytosponge: a qualitative study.Cytosponge的患者体验：一项定性研究。
Frontline Gastroenterol. 2023 Sep 11;15(1):28-34. doi: 10.1136/flgastro-2023-102484. eCollection 2024 Jan.
本文引用的文献
1
Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial.患者对 Cytosponge 检测的体验和看法：来自 BEST3 试验的混合方法分析。
BMJ Open. 2022 Apr 7;12(4):e054258. doi: 10.1136/bmjopen-2021-054258.
2
Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.使用 Cytosponge 生物标志物面板对内镜 Barrett 食管监测进行优先级排序：一项横断面研究及后续真实世界前瞻性试点研究。
Lancet Oncol. 2022 Feb;23(2):270-278. doi: 10.1016/S1470-2045(21)00667-7. Epub 2022 Jan 11.
3
The Newcastle ENDOPREM™: a validated patient reported experience measure for gastrointestinal endoscopy.纽卡斯尔 ENDOPREM™：一种经过验证的用于胃肠内窥镜检查的患者报告体验测量工具。
BMJ Open Gastroenterol. 2021 Oct;8(1). doi: 10.1136/bmjgast-2021-000653.
4
Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.Cytosponge-三叶因子 3 与常规护理在初级保健环境中识别 Barrett 食管：一项多中心、实用、随机对照试验。
Lancet. 2020 Aug 1;396(10247):333-344. doi: 10.1016/S0140-6736(20)31099-0.
5
Patient experience of gastrointestinal endoscopy: informing the development of the Newcastle ENDOPREM™.胃肠道内镜检查的患者体验：为纽卡斯尔ENDOPREM™的开发提供信息。
Frontline Gastroenterol. 2020 Jan 13;11(3):209-217. doi: 10.1136/flgastro-2019-101321. eCollection 2020.
6
British Society of Gastroenterology position statement on patient experience of GI endoscopy.英国胃肠病学会关于胃肠内镜检查患者体验的立场声明。
Gut. 2020 Sep;69(9):1. doi: 10.1136/gutjnl-2019-319207. Epub 2019 Sep 10.
7
Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study.一种用于诊断巴雷特食管的微创细胞采样装置结合三叶因子3表达评估的评价：一项多中心病例对照研究。
PLoS Med. 2015 Jan 29;12(1):e1001780. doi: 10.1371/journal.pmed.1001780. eCollection 2015 Jan.
Zotero 插件